QQQ   437.93 (+0.61%)
AAPL   180.14 (-0.71%)
MSFT   408.77 (+0.26%)
META   487.39 (+0.70%)
GOOGL   137.08 (+0.51%)
AMZN   174.67 (+0.87%)
TSLA   200.25 (-0.89%)
NVDA   791.40 (+1.90%)
NIO   5.66 (+4.24%)
AMD   189.52 (+7.35%)
BABA   74.07 (-0.70%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   89.70 (-0.01%)
CGC   3.28 (-2.38%)
GE   155.76 (+0.10%)
DIS   111.06 (+0.23%)
AMC   4.28 (-14.23%)
PFE   26.76 (-1.04%)
PYPL   60.34 (+0.15%)
XOM   104.68 (+0.35%)
QQQ   437.93 (+0.61%)
AAPL   180.14 (-0.71%)
MSFT   408.77 (+0.26%)
META   487.39 (+0.70%)
GOOGL   137.08 (+0.51%)
AMZN   174.67 (+0.87%)
TSLA   200.25 (-0.89%)
NVDA   791.40 (+1.90%)
NIO   5.66 (+4.24%)
AMD   189.52 (+7.35%)
BABA   74.07 (-0.70%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   89.70 (-0.01%)
CGC   3.28 (-2.38%)
GE   155.76 (+0.10%)
DIS   111.06 (+0.23%)
AMC   4.28 (-14.23%)
PFE   26.76 (-1.04%)
PYPL   60.34 (+0.15%)
XOM   104.68 (+0.35%)
QQQ   437.93 (+0.61%)
AAPL   180.14 (-0.71%)
MSFT   408.77 (+0.26%)
META   487.39 (+0.70%)
GOOGL   137.08 (+0.51%)
AMZN   174.67 (+0.87%)
TSLA   200.25 (-0.89%)
NVDA   791.40 (+1.90%)
NIO   5.66 (+4.24%)
AMD   189.52 (+7.35%)
BABA   74.07 (-0.70%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   89.70 (-0.01%)
CGC   3.28 (-2.38%)
GE   155.76 (+0.10%)
DIS   111.06 (+0.23%)
AMC   4.28 (-14.23%)
PFE   26.76 (-1.04%)
PYPL   60.34 (+0.15%)
XOM   104.68 (+0.35%)
QQQ   437.93 (+0.61%)
AAPL   180.14 (-0.71%)
MSFT   408.77 (+0.26%)
META   487.39 (+0.70%)
GOOGL   137.08 (+0.51%)
AMZN   174.67 (+0.87%)
TSLA   200.25 (-0.89%)
NVDA   791.40 (+1.90%)
NIO   5.66 (+4.24%)
AMD   189.52 (+7.35%)
BABA   74.07 (-0.70%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   89.70 (-0.01%)
CGC   3.28 (-2.38%)
GE   155.76 (+0.10%)
DIS   111.06 (+0.23%)
AMC   4.28 (-14.23%)
PFE   26.76 (-1.04%)
PYPL   60.34 (+0.15%)
XOM   104.68 (+0.35%)
NASDAQ:CPRX

Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis

$15.86
+1.30 (+8.93%)
(As of 12:57 PM ET)
Today's Range
$15.28
$16.50
50-Day Range
$13.18
$17.29
52-Week Range
$11.09
$18.22
Volume
2.26 million shs
Average Volume
1.52 million shs
Market Capitalization
$1.86 billion
P/E Ratio
30.50
Dividend Yield
N/A
Price Target
$25.80

Catalyst Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
65.2% Upside
$25.80 Price Target
Short Interest
Bearish
6.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.28mentions of Catalyst Pharmaceuticals in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$2.63 M Sold Last Quarter
Proj. Earnings Growth
23.20%
From $1.81 to $2.23 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.82 out of 5 stars

Medical Sector

63rd out of 958 stocks

Pharmaceutical Preparations Industry

19th out of 450 stocks

CPRX stock logo

About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CPRX Stock Price History

CPRX Stock News Headlines

Catalyst: Q4 Earnings Snapshot
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Catalyst Pharmaceuticals, Inc. (CPRX)
Biotech And Pharma Diversification Pays Off
See More Headlines
Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CPRX
Employees
82
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$25.80
High Stock Price Target
$30.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+77.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$83.08 million
Pretax Margin
23.20%

Debt

Sales & Book Value

Annual Sales
$214.20 million
Cash Flow
$0.82 per share
Book Value
$2.89 per share

Miscellaneous

Free Float
103,340,000
Market Cap
$1.71 billion
Optionable
Optionable
Beta
0.93

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives















CPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings
or view top-rated stocks.

What is Catalyst Pharmaceuticals' stock price target for 2024?

3 analysts have issued 12 month price targets for Catalyst Pharmaceuticals' stock. Their CPRX share price targets range from $24.00 to $30.00. On average, they expect the company's stock price to reach $25.80 in the next year. This suggests a possible upside of 65.2% from the stock's current price.
View analysts price targets for CPRX
or view top-rated stocks among Wall Street analysts.

How have CPRX shares performed in 2024?

Catalyst Pharmaceuticals' stock was trading at $16.81 on January 1st, 2024. Since then, CPRX shares have decreased by 7.1% and is now trading at $15.62.
View the best growth stocks for 2024 here
.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 5,670,000 shares, an increase of 20.9% from the January 31st total of 4,690,000 shares. Based on an average daily volume of 1,390,000 shares, the days-to-cover ratio is currently 4.1 days. Approximately 6.2% of the shares of the company are short sold.
View Catalyst Pharmaceuticals' Short Interest
.

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CPRX earnings forecast
.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 EPS for the quarter, meeting the consensus estimate of $0.10. The biopharmaceutical company earned $35.95 million during the quarter, compared to the consensus estimate of $34.47 million. Catalyst Pharmaceuticals had a net margin of 17.81% and a trailing twelve-month return on equity of 19.32%. During the same quarter last year, the firm posted $0.11 earnings per share.

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?

Catalyst Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $455.0 million-$475.0 million, compared to the consensus revenue estimate of $463.2 million.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.06%), Dimensional Fund Advisors LP (2.21%), Boston Partners (1.31%), Northern Trust Corp (1.21%), Opaleye Management Inc. (1.07%) and LSV Asset Management (1.05%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends
.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CPRX) was last updated on 2/29/2024 by MarketBeat.com Staff

From Our Partners